Michael Lassmann. Senior Physicist. PhD. Curriculum vitae PERSONAL INFORMATION WORK EXPERIENCE. June 1988 Present

Transcription

1 Curriculum vitae PERSONAL INFORMATION Michael Lassmann WORK EXPERIENCE June 1988 Present Senior Physicist University Hospital Würzburg (Germany) EDUCATION AND TRAINING April 1983 May 1988 PhD University Würzburg (Germany) ADDITIONAL INFORMATION Expertise Internal Dosimetry Publications 1. Barrio MJ, Spick C, Radu CG, et al. Human Biodistribution and Radiation Dosimetry of 18F- Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. J Nucl Med. 2017;58: Zimmerman BE, Grosev D, Buvat I, et al. Multi-centre evaluation of accuracy and reproducibility of planar and SPECT image quantification: An IAEA phantom study. Z Med Phys. 2017;27: Eberlein U, Lassmann M. Internal Dosimetry: Principles and Applications to NET. In: Pacak K, Taïeb D, eds. Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. Cham: Springer International Publishing; 2017: Barquero R, Garcia HP, Incio MG, et al. 131I activity quantification of gamma camera planar images. Phys Med Biol. 2017;62: Kesner AL, Poli GL, Beykan S, Lassmann M. The IAEA Radiotracer Biodistribution Template - A community resource for supporting the standardization and reporting of radionuclide pre-dosimetry data. Phys Med Eberlein U, Cremonesi M, Lassmann M. Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive? J Nucl Med. 2017;58:97S-103S. 7. Schottelius M, Osl T, Poschenrieder A, et al. [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics. 2017;7: Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose Mapping after Endoradiotherapy with 177Lu-DOTATATE/-TOC by One Single Measurement after Four Days. J Nucl Med Chiesa C, Sjogreen Gleisner K, Flux G, et al. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. Eur J Nucl Med Mol Imaging Werner RA, Weich A, Higuchi T, et al. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. Theranostics. 2017;7: Verburg FA, Luster M, Giovanella L, et al. The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients. Eur J Nucl Med Mol Imaging. 2017;44: Flux GD, Verburg FA, Chiesa C, et al. Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. J Nucl Med. 2017;58: Nicolas GP, Beykan S, Bouterfa H, et al. Safety, Biodistribution, and Radiation Dosimetry of 68Ga- OPS202 (68Ga-NODAGA-JR11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. J Nucl Med Salas-Ramirez M, Tran-Gia J, Kesenheimer C, et al. Quantification of fat fraction in lumbar vertebrae: correlation with age and implications for bone marrow dosimetry in molecular radiotherapy. Phys Med Biol Tran-Gia J, Lassmann M. Optimizing Image Quantification for Lu-177 SPECT/CT Based on a 3D Printed 2-Compartment Kidney Phantom. J Nucl Med /1/18 European Union, Page 1 / 11

2 16. Flux GD, Sjogreen Gleisner K, Chiesa C, et al. From fixed activities to personalized treatments in radionuclide therapy: lost in translation? Eur J Nucl Med Mol Imaging Nicolas G, Baum R, Herrmann K, et al. Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201. Neuroendocrinology. 2017;105: Lassmann M, Eberlein U. Radiation Risk from Medical Exposure in Children. In: Mansi L, Lopci E, Cuccurullo V, Chiti A, eds. Clinical Nuclear Medicine in Pediatrics: Springer International Publishing; 2016: Fahey F, Ted Treves S, Lassmann M. Dose optimization in pediatric nuclear medicine. Clinical and Translational Imaging. 2016;4: Lassmann M, Pedroli G. Dose optimization in nuclear medicine. Clinical and Translational Imaging. 2016;4: Eberlein U, Scherthan H, Bluemel C, et al. The relationship between absorbed dose and DNA Damage in Lymphocytes after radionuclide therapy. Radiotherapy and Oncology. Vol 118: Elsevier; 2016:S37-S Lassmann M. Quantitative Theranostics in Nuclear Medicine. Radiotherapy and Oncology. 2016;118:S65-S Lassmann M, Eberlein U. Radiation Safety and Dosimetry. In: Herrmann K, Nieweg EO, Povoski PS, eds. Radioguided Surgery: Current Applications and Innovative Directions in Clinical Practice. Cham: Springer International Publishing; 2016: Wendler T, Eberlein U, Lassmann M. Physics of Radioguided Surgery: Basic Principles and Methods of Radiation Detection. In: Herrmann K, Nieweg EO, Povoski PS, eds. Radioguided Surgery: Current Applications and Innovative Directions in Clinical Practice. Cham: Springer International Publishing; 2016: Treves ST, Gelfand MJ, Goodkind A, Fahey FH, Lassmann M. Standardization of pediatric nuclear medicine administered radiopharmaceutical activities: the SNMMI/EANM Joint Working Group. Clinical and Translational Imaging. 2016;4: Beykan S, Dam JS, Eberlein U, et al. 177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model. EJNMMI Research. 2016;6: Gelfand M, Treves ST, Lassmann M, Fahey F, Alessio A, Parisi M. A decade of dose reduction in pediatric nuclear medicine. Journal of Nuclear Medicine. Vol 57; 2016: Kesner A, Poli GL, Beykan S, Lassmann M. Standardized biodistribution template for dosimetry collection and reporting. Journal of Nuclear Medicine. Vol 57; 2016: Tran-Gia J, Schlögl S, Lassmann M. Design and Fabrication of Kidney Phantoms for Internal Radiation Dosimetry Using 3D Printing Technology. Journal of Nuclear Medicine. 2016;57: Lassmann M, Eberlein U, Lopci E, Chiti A. Standardization of administered activities in paediatric nuclear medicine: the EANM perspective. Eur J Nucl Med Mol Imaging. 2016;43: Boschi S, Lee JT, Beykan S, et al. Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur J Nucl Med Mol Imaging. 2016;43: Werner RA, Beykan S, Higuchi T, et al. The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. Oncotarget. 2016;7: Fahey FH, Bom HH, Chiti A, et al. Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 2-Current Standards and the Path Toward Global Standardization. J Nucl Med. 2016;57: Bluemel C, Krebs M, Polat B, et al. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med. 2016;41: Machado JS, Beykan S, Herrmann K, Lassmann M. Recommended administered activities for (68)Ga-labelled peptides in paediatric nuclear medicine. Eur J Nucl Med Mol Imaging. 2016;43: Herrmann K, Schottelius M, Lapa C, et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J Nucl Med. 2016;57: Eberlein U, Scherthan H, Bluemel C, et al. DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy. J Nucl Med. 2016;57: Ljungberg M, Celler A, Konijnenberg MW, et al. MIRD Pamphlet No. 26: Joint EANM/MIRD 17/1/18 European Union, Page 2 / 11

3 Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. J Nucl Med. 2016;57: Nicolas GP, Kaul F, Mena R, et al. Gastroenteropancreatic Neuroendocrine Tumor Patients Imaged Favorably With Somatostatin Receptor Antagonist: Results of a Phase I/II Study Comparing Ga-68-OPS202 With Ga-68-DOTATOC PET/CT. Pancreas. Vol 45; 2016: Dietlein M, Eschner W, Grunwald F, Lassmann M, Verburg FA, Luster M. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer Version 4. Nuklearmedizin-Nuclear Medicine. 2016;55: Salas M, Schloegl S, Tran-Gia J, Kesenheimer C, Haenscheid H, Lassmann M. Simulation of radioactive sources in a bone cavity to evaluated the activity quantification in bone marrow dosimetry. European Journal of Nuclear Medicine and Molecular Imaging. 2016;43:S412-S Beykan S, Nicolas GP, Fani M, et al. First Clinical Study of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET): Patient Dosimetry Assessment with the Somatostatin Receptor Antagonist Ga-68-OPS202. European Journal of Nuclear Medicine and Molecular Imaging. 2016;43:S89-S Wester HJ, Keller U, Schottelius M, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5: Kletting P, Schimmel S, Hanscheid H, et al. The NUKDOS software for treatment planning in molecular radiotherapy. Z Med Phys. 2015;25: Herrmann K, Lapa C, Wester HJ, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med. 2015;56: Pacilio M, Amato E, Lanconelli N, et al. Differences in 3D dose distributions due to calculation method of voxel S-values and the influence of image blurring in SPECT. Phys Med Biol. 2015;60: Hanscheid H, Fernandez M, Lassmann M. The absorbed dose to blood from blood-borne activity. Phys Med Biol. 2015;60: Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56: Eberlein U, Peper M, Fernandez M, Lassmann M, Scherthan H. Calibration of the gamma-h2ax DNA double strand break focus assay for internal radiation exposure of blood lymphocytes. PLoS One. 2015;10:e Fahey FH, Bom HH, Chiti A, et al. Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1-statement of the issue and a review of available resources. J Nucl Med. 2015;56: Werner RA, Bluemel C, Lassmann M, et al. SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach. Clin Nucl Med. 2015;40:e Eberlein U, Nowak C, Bluemel C, et al. DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2015;42: Machado JS, Beykan S, Lassmann M. Dosage in Pediatric Nuclear Medicine Diagnostics in Daily Practice. European Journal of Nuclear Medicine and Molecular Imaging. Vol 42; 2015:S350-S Machado JS, Beykan S, Lassmann M. Recommended Administered Activity for Ga-68 labelled peptides in Pediatric Nuclear Medicine. European Journal of Nuclear Medicine and Molecular Imaging. Vol 42; 2015:S349-S Herrmann K, Schottelius M, Lapa C, et al. First-in-man experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labelled pentixather in advanced stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med. 2015/11/14 ed; Pfestroff A, Luster M, Jilg CA, et al. Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. Eur J Nucl Med Mol Imaging. 2015;42: Bluemel C, Herrmann K, Giammarile F, et al. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. Eur J Nucl Med Mol Imaging. 2015;42: Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med. 2015;56: Lapa C, Spehl TS, Brumberg J, et al. Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. Am J Nucl Med Mol Imaging. 2015;5: Lassmann M, Eberlein U. Radiation Dosimetry Aspects of (177)Lu. Curr Radiopharm. 2015;8:139-17/1/18 European Union, Page 3 / 11

4 Lassmann MM, Hanscheid H. Individual dosimetry in radioiodine therapy. Onkologe. 2015;21: Hänscheid H, Lassmann M, Verburg FA. Dose optimization in nuclear medicine therapy of benign and malignant thyroid diseases. Clinical and Translational Imaging. 2015;4: Beykan S, Dam JS, Eberlein U, et al. [177Lu]-OPS201 targeting somatostatin receptors: In vivo biodistribution and dosimetry in a pig model. European Journal of Nuclear Medicine and Molecular Imaging. Vol 42; 2015:S204-S Beykan S, Lassmann M, Schlogl S. Image Quality Parameters and Quantification Issues with Y-90 Bremsstrahlung SPECT/CT. European Journal of Nuclear Medicine and Molecular Imaging. Vol 42; 2015:S750-S Eberlein U, Nowak C, Lapa C, et al. Different DNA Damage Repair Rates in Blood Lymphocytes after Peptide Receptor Radionuclide Therapy and Radioiodine Therapy of Thyroid Cancer. European Journal of Nuclear Medicine and Molecular Imaging. Vol 42; 2015:S114-S Werner RA, Beykan S, Lapa C, et al. Early assessment of renal impairment in patients undergoing Peptide Receptor Radionuclide Therapy evaluated by MAG3 renal scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging. Vol 42; 2015:S83-S Schottelius M, Osl T, Poschenrieder A, et al. [(177)]Lu-pentixather: preclinical and first patient results with a highly promising CXCR4-directed endoradiotherapeutic agent. Journal of Nuclear Medicine. Vol 56; Bluemel C, Christian V, Buck A, et al. Additional value of PSMA-PET/CT in biochemical recurrence during follow-up of patients with prostate cancer. Journal of Nuclear Medicine. Vol 56; Lapa C, Herrmann K, Wester HJ, et al. Biodistribution and radiation dosimetry for the novel chemokine receptor CXCR4-targeting probe [Ga-68] pentixafor. Journal of Nuclear Medicine. Vol 56; Willowson KP, Tapner M, Team QI, Bailey DL. A multicentre comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres : The QUEST Phantom Study. Eur J Nucl Med Mol Imaging. 2015;42: Lassmann M. Dosimetry and Radiation Exposure of Patients. In: Kampen UW, Fischer M, eds. Local Treatment of Inflammatory Joint Diseases: Benefits and Risks. Cham: Springer International Publishing; 2015: Kletting P, Schimmel S, Kestler HA, et al. Erratum: Molecular radiotherapy: The NUKFIT software for calculating the time-integrated activity coefficient [Med. Phys. 40, (2013)]. Med Phys. 2014;41: Chiesa C, Lambert B, Maccauro M, et al. Pretreatment Dosimetry in HCC Radioembolization with 90Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of 99mTc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres. J Nucl Med. 2014;55: Flux GD, Bardies M, Lassmann M. Biting the magic bullet: celebrating a decade of the EANM Dosimetry Committee. Eur J Nucl Med Mol Imaging. 2014;41: Isaias IU, Spiegel J, Brumberg J, et al. Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease. Front Aging Neurosci. 2014;6: Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K. Clinical use of bonetargeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol. 2014;6: Spottswood SE, Pfluger T, Bartold SP, et al. SNMMI and EANM practice guideline for meckel diverticulum scintigraphy 2.0. J Nucl Med Technol. 2014;42: Strigari L, Konijnenberg M, Chiesa C, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41: Lassmann M, Treves ST. Pediatric Radiopharmaceutical Administration: harmonization of the 2007 EANM Paediatric Dosage Card (Version ) and the 2010 North American Consensus guideline. Eur J Nucl Med Mol Imaging. 2014;41: Lassmann M, Eberlein U, Tosi G, Chiti A. (18)F-FDG PET/CT scans for children and adolescents. Lancet Oncol. 2014;15:e Treves ST, Lassmann M, Group ESPDHW. International guidelines for pediatric radiopharmaceutical administered activities. J Nucl Med. 2014;55: Hanscheid H, Lassmann M, Buck AK, Reiners C, Verburg FA. The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma. Phys Med Biol. 17/1/18 European Union, Page 4 / 11

5 2014;59: Hanscheid H, Fernandez M, Eberlein U, Lassmann M. Self-irradiation of the blood from selected nuclides in nuclear medicine. Phys Med Biol. 2014;59: Frey E, Green A, Lassmann M, Ljungberg M, Poli GL, Zimmerman B. International intercomparison of absolute quantification in nuclear medicine. J NUCL MED MEETING ABSTRACTS. Vol 55; 2014: Bardiès M, Lassmann M. Monte Carlo Methods in Nuclear Medicine. In: Baum PR, ed. Therapeutic Nuclear Medicine. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014: Brumberg J, Isaias IU, Lorenz R, et al. Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging. Vol 41; 2014:S275-S Kletting P, Schimme S, Fernandez M, et al. Application of the NUKDOS Software in Peptide Receptor Radionuclide Therapy. European Journal of Nuclear Medicine and Molecular Imaging. Vol 41; 2014:S220-S Eberlein U, Lassmann M, Peper M, Fernandez M, Scherthan H. In-vitro dose calibration of DNA damage in blood lymphocytes after internal irradiation of whole blood with I-131 and Lu-177 using the DSB focus assay. European Journal of Nuclear Medicine and Molecular Imaging. Vol 41; 2014:S294- S Brumberg J, Lapa C, Spehl T, et al. Influence of CT-based attenuation correction on presynaptic dopamine transporter SPECT with I-123-FP-CIT. European Journal of Nuclear Medicine and Molecular Imaging. Vol 41; 2014:S361-S Eberlein U, Kaufmann J, Jodai L, Bouterfa H, Lassmann M, Jensen SB. [68Ga]-OPS202 targeting somatostatin receptors: In vivo biodistribution and dosimetry in a pig model. European Journal of Nuclear Medicine and Molecular Imaging. Vol 41; 2014:S317-S Eberlein U, Peper M, Bluemel C, et al. Blood-based dosimetry in radiopeptide therapy patients using the DSB focus assay. European Journal of Nuclear Medicine and Molecular Imaging. Vol 41; 2014:S284-S Fernandez M, Hanscheid H, Kletting P, Glatting G, Nosske D, Lassmann M. Comparison of SPECT/CT activity quantification accuracy with and without background. European Journal of Nuclear Medicine and Molecular Imaging. Vol 41; 2014:S555-S Kletting P, Schimmel S, Haenscheid H, et al. NUKDOS: A software tool for dosimetry prior to molecular radiotherapy. Journal of Nuclear Medicine. Vol 55; Kletting P, Schimmel S, Kestler HA, et al. Molecular radiotherapy: The NUKFIT software for calculating the time- integrated activity coefficient (vol 40, pg , 2013). Med Phys. 2014; Lassmann M, Treves ST, EANM SNMMI Paediatric Dosage Harmonization Working Group. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version ) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging. 2014;41: Wild D, Fani M, Fischer R, Pozzo L, Kaul F, Krebs S. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014; Kletting P, Schimmel S, Kestler HA, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013;40: Preylowski V, Schlogl S, Schoenahl F, et al. Is the image quality of I-124-PET impaired by an automatic correction of prompt gammas? PLoS One. 2013;8:e Fernandez M, Hanscheid H, Mauxion T, et al. A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation. Med Phys. 2013;40: Glatting G, Bardies M, Lassmann M. Treatment planning in molecular radiotherapy. Z Med Phys. 2013;23: Hänscheid H, Canzi C, Eschner W, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. Eur J Nucl Med Mol Imaging. 2013;40: Lonsdale MN, Bardies M, Boellaard R, et al. EFOMP and EANM: joint recommendations for a curriculum for the education and training of physicists in nuclear medicine. Eur J Nucl Med Mol Imaging. 2013;40: Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-hodgkin 17/1/18 European Union, Page 5 / 11

6 lymphoma. Curr Radiopharm. 2013;6: Lonsdale MN, Lassmann M. EANM perspective. Radiat Prot Dosimetry. 2013;153: Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40: Eberlein U, Lassmann M. Dosimetry of [68Ga]-labeled compounds. Appl Radiat Isot. 2013;76: Del Guerra A, Bardies M, Belcari N, et al. Curriculum for education and training of medical physicists in nuclear medicine: recommendations from the EANM Physics Committee, the EANM Dosimetry Committee and EFOMP. Phys Med. 2013;29: Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013; Kletting P, Schimmel S, Kestler HA, Hanscheid H, Luster M, Fernandez M. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013; Dewaraja YK, Ljungberg M, Green AJ, et al. MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med. 2013;54: Eberlein U, Lassmann M, Vase K, et al. Biodistribution and dosimetry of [68Ga]-DOTASOM targeting somatostatin receptors in a pig model. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39:S325-S Preylowski V, Schlogl S, Jorg G, Samnick S, Lassmann M. Prompt Gamma Compensation and image quality of I-124 PET. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39:S394-S Kletting P, Schimmel S, Hanscheid H, et al. A Software Package to Calculate the Residence Time and its Accuracy in Targeted Radionuclide Therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39:S352-S Tomas Fernandez M, Preylowski V, Schlogl S, et al. Influence of the reconstruction parameters on image quantification with SPECT/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39:S Preylowski V, Hanscheid H, Jorg G, Samnick S, Lassmann M. Setting up dose calibrators for I- 124 measurements. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39:S384- S Tomas MF, Hanscheid H, Eberlein U, Lassmann M. Self-irradiation of the blood by Y-90, I-131 and Lu-177. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39:S322-S Eberlein U, Lassmann M, Schrock G, Diessl S, Buck AK, Scherthan H. Early DNA repair focus formation in blood cells after thyroid cancer therapy with I-131. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39:S336-S Tomas MF, Hanscheid H, Mauxion T, et al. Methodology to accurately recalculate Voxel S Values for arbitrary voxel size in targeted radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39:S199-S Chiesa C, Luster M, Lassmann M. 4th international symposium on targeted radiotherapy and dosimetry (ISTARD): best ranked abstract publication. Q J Nucl Med Mol Imaging. 2012;56: Reiners C, Lassmann M, Luster M. Recombinant human thyrotropin: safety and quality of life evaluation. J Endocrinol Invest. 2012;35: Kreissl MC, Hanscheid H, Lohr M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiation Oncology. 2012;7: Savolainen S, Konijnenberg M, Bardies M, et al. Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. Eur J Nucl Med Mol Imaging. 2012;39: Bundschuh R, Eberlein, U., Lassmann, M., Buck, A.K. PET/CT and SPECT/CT in Oncology How can the Radiation Exposure be Reduced? Der Nuklearmediziner. 2012;35: Dewaraja YK, Frey EC, Sgouros G, et al. MIRD pamphlet No. 23: quantitative SPECT for patientspecific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53: Lassmann M, Chiesa C, Flux G, Bardies M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38: Lassmann M. [Regarding the effective dose in the diagnosis for patients -- specific dosimetry in 17/1/18 European Union, Page 6 / 11

7 nuclear medicine therapy]. Nuklearmedizin. 2011;50: Eberlein U, Broer JH, Vandevoorde C, et al. Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine - a review. Eur J Nucl Med Mol Imaging. 2011;38: Hanscheid H, Reiners C, Goulko G, et al. Facing the nuclear threat: thyroid blocking revisited. J Clin Endocrinol Metab. 2011;96: Reiners C, Hanscheid H, Luster M, Lassmann M, Verburg FA. Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol. 2011;7: Lassmann M, Hanscheid H, Verburg FA, Luster M. The use of dosimetry in the treatment of differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2011;55: Chiesa C, Lassmann M. Dosimetry in nuclear medicine therapy. Q J Nucl Med Mol Imaging. 2011;55: Verburg FA, Lassmann M, Mader U, Luster M, Reiners C, Hanscheid H. The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients. Eur J Nucl Med Mol Imaging. 2011;38: Verburg FA, Luster M, Lassmann M, Reiners C. (131)I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies. Nuklearmedizin. 2011;50:93-99; quiz N Eberlein U, Broer JH, Vandevoorde C, et al. PEDDOSE.NET: Dosimetry and Health Effects of Diagnostic Applications of Radiopharmaceuticals with Particular Emphasis on the Use in Children and Adolescents. European Journal of Nuclear Medicine and Molecular Imaging. 2011;38:S438-S Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I II study. Eur J Nucl Med Mol Imaging. 2011; Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011; Cescato R, Waser B, Fani M, Reubi JC. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011; Hanscheid H, Lassmann M, Reiners C. Dosimetry prior to I-131-therapy of benign thyroid disease. Z Med Phys. 2011;21: Verburg FA, Luster M, Lassmann M, Reiners C. 131I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies. Nuklearmedizin. 2010; Hindorf C, Glatting G, Chiesa C, Linden O, Flux G. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37: Lassmann M. [Dosimetry of short-ranged radionuclides]. Nuklearmedizin. 2010;49 Suppl 1:S Lassmann M, Strigari L, Bardies M. Dosimetry is alive and well. Cancer Biother Radiopharm. 2010;25: Lassmann M, Hanscheid H, Gassen D, et al. In vivo formation of gamma-h2ax and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2010;51: Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37: Verburg FA, Hänscheid H, Biko J, et al. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2010;37: Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Vecchio S. 111Inpentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010; Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer. 2010;17:R Verburg FA, Hanscheid H, Biko J, et al. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2010;37: Hänscheid H, Lassmann M, Luster M, Kloos RT, Reiners C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. 17/1/18 European Union, Page 7 / 11

8 Endocr Relat Cancer. 2009;16: Chiesa C, Castellani MR, Vellani C, et al. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2009;53: Elisei R, Schlumberger M, Driedger A, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009;94: Alkureishi LW, Burak Z, Alvarez JA, et al. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Ann Surg Oncol. 2009;16: Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36: Essen M, Krenning EP, Kam BL, Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009; Hanscheid H, Lassmann M, Luster M, Kloos RT, Reiners C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2009;16: Lassmann M. The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging. 2008;35: Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35: Lassmann M, Biassoni L, Monsieurs M, Franzius C. The new EANM paediatric dosage card: additional notes with respect to F-18. Eur J Nucl Med Mol Imaging. 2008;35: Lassmann M, Hanscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35: Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure guidelines for 131I-metaiodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35: Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008; Lassmann M. Introduction and concepts of internal dosimetry. Radiotherapy and Oncology. 2007;84:S106-S Tennvall J, Brans B, Lassmann M. EANM procedure guideline for P-32 phosphate treatment of myeloproliferative diseases. European Journal of Nuclear Medicine and Molecular Imaging. 2007;34: Lassmann M, Brans BT, Flux GD. 2nd International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry - September 30 October 4, Athens, Greece. Cancer Biotherapy and Radiopharmaceuticals. 2007;22: Buscombe J, Paganelli G, Burak ZE, et al. Sentinel node in breast cancer procedural guidelines. Eur J Nucl Med Mol Imaging. 2007;34: Andermann P, Schlogl S, Mader U, Luster M, Lassmann M, Reiners C. Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound. Nuklearmedizin. 2007;46: Lassmann M, Hänscheid H. Spatial dose mapping for individualizing radioiodine treatment. J Nucl Med. 2007;48: Luster M, Lassmann M, Freudenberg LS, Reiners C. Thyroid cancer in childhood: management strategy, including dosimetry and long-term results. Hormones (Athens). 2007;6: Dietlein M, Dressler J, Eschner W, et al. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)]. Nuklearmedizin. 2007;46: Dietlein M, Dressler J, Eschner W, et al. [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)]. Nuklearmedizin. 2007;46: Dietlein M, Dressler J, Eschner W, et al. [Procedure guideline for radioiodine test (Version 3)]. Nuklearmedizin. 2007;46: Flux G, Bardies M, Chiesa C, et al. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging. 2007;34: /1/18 European Union, Page 8 / 11

9 173. Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F. The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging. 2007;34: Tennvall J, Fischer M, Bischof Delaloye A, et al. EANM procedure guideline for radioimmunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34: Bardies M, Flux G, Lassmann M, Monsieurs M, Savolainen S, Strand SE. Quantitative imaging for clinical dosimetry. Nuclear Instruments & Methods in Physics Research Section a-accelerators Spectrometers Detectors and Associated Equipment. 2006;569: Geworski L, Zophel K, Rimpler A, et al. Radiation exposure in Y-90-Zevalin therapy - Results of a prospective multicentre trial. Nuklearmedizin-Nuclear Medicine. 2006;45: Reiners C, Lassmann M, Hänscheid H. A perspective on post-chernobyl radioablation in young females. J Nucl Med. 2006;47: Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhtsh or hormone withdrawal. J Nucl Med. 2006;47: Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91: Flux G, Bardies M, Monsieurs M, Savolainen S, Strands SE, Lassmann M. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys. 2006;16: Geworski L, Zophel K, Rimpler A, et al. [Radiation exposure in (90)Y-Zevalin therapy: results of a prospective multicentre trial]. Nuklearmedizin. 2006;45:82-86; quiz N Schlogl S, Andermann P, Luster M, Reiners C, Lassmann M. A novel thyroid phantom for ultrasound volumetry: determination of intraobserver and interobserver variability. Thyroid. 2006;16: Lassmann M, Brans B, Behr T. Introduction 1st International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry. Cancer Biotherapy and Radiopharmaceuticals. 2005;20: Lassmann M, Hänscheid H, Reiners C, Thomas SR. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhtsh. J Nucl Med. 2005;46: ; author reply Lassmann M, Luster M, Hänscheid H, Reiners C. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2005;46: Hesse B, Tagil K, Cuocolo A, et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging. 2005;32: Luster M, Lippi F, Jarzab B, et al. rhtsh-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005;12: Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; Lassmann M, Hänscheid H, Luster M, Reiners C. How to determine blood doses and remnant biokinetics for thyroid ablation therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2004;31:S259-S Luster M, Ladenson P, Pacini F, et al. Recombinant TSH or thyroid hormone withdrawal? A comparison of I-131 remnant ablation rates in thyroid cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 2004;31:S290-S Lassmann M, Hänscheid H, Reiners C. [Simple measurement of intrathyroid iodine kinetics]. Nuklearmedizin. 2004;43:N38-39; author reply N Lassmann M, Luster M, Hänscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45: Hänscheid H, Lassmann M, Aulbach F, Reiners C. Monitoring of (131)l incorporation in nuclear medicine personnel by self accomplished measurements. Nuklearmedizin-Nuclear Medicine. 2003;42: Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30: Dietlein M, Dressler J, Eschner W, et al. [Procedure guideline for radioiodine test (version 2)]. 17/1/18 European Union, Page 9 / 11

10 Nuklearmedizin. 2003;42: Lassmann M, Reiners C. A DICOM based PACS for nuclear medicine. Nuklearmedizin-Nuclear Medicine. 2002;41: Lassmann M, Nosske D, Reiners C. Therapy of ankylosing spondylitis with 224Ra-radium chloride: dosimetry and risk considerations. Radiat Environ Biophys. 2002;41: Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med. 2002; Li WB, Friedland W, Pomplun E, et al. Track structures and dose distributions from decays of (131)I and (125)I in and around water spheres simulating micrometastases of differentiated thyroid cancer. Radiat Res. 2001;156: Schlogl S, Werner E, Lassmann M, et al. The use of three-dimensional ultrasound for thyroid volumetry. Thyroid. 2001;11: Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2000;85: Luster M, Reinhardt W, Korber C, et al. The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest. 2000;23: Reiners C, Lassmann M. Radiation protection principles for radioiodine therapy. Kerntechnik. 1999;64: Reiners C, Luster M, Lassmann M. Clinical experience with recombinant human thyroidstimulating hormone (rhtsh): whole-body scanning with iodine-131. J Endocrinol Invest. 1999;22: Reiners C, Lassmann M. Radioiodine (131I) treatment of hyperthyroidism: radiation protection and quality assurance. Eur J Nucl Med. 1999;26: Reiners C, Lassmann M. Assessment of patient exposure in nuclear medicine. Radiation Protection Dosimetry. 1998;80: Lassmann M, Hänscheid H, Schelper LF, Korber C, Reiners C. Measurement of incorporation in family members of patients with benign thyroid diseases after radioiodine therapy. Nuklearmedizin- Nuclear Medicine. 1998;37: Reiners C, Hänscheid H, Lassmann M, et al. X-ray fluorescence analysis (XFA) of thyroidal iodine content (TIC) with an improved measuring system. Exp Clin Endocrinol Diabetes. 1998;106 Suppl 3:S Farahati J, Lassmann M, Scheubeck M, et al. Effect of specific activity on organ uptake of iodine- 123-meta-iodobenzylguanidine in humans. Int J Oncol. 1997;10: Farahati J, Bier D, Scheubeck M, et al. Effect of specific activity on cardiac uptake of iodine-123- MIBG. J Nucl Med. 1997;38: Meredith RF, Partridge EE, Alvarez RD, Khazaeli MB, Plott G, Russell CD. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-cc49. J Nucl Med. 1996; Lassmann M, Roos H, Kellerer AM. Lateral Dose Distribution of Proton-Beams at Energies from 4 to 11 Mev. Radiat Prot Dosimetry. 1994;52: Schneider P, Lassmann M, Borner W. Early Results of Lumbar Dual-Energy X-Ray Absorptiometry (Dexa) Compared with Dual-Energy Quantitative Computer-Tomography. Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Neuen Bildgebenden Verfahren. 1994;160: Schneider P, Lassmann M, Borner W. [Letter concerning the article: Initial results of lumbar dualenergy roentgen absorptiometry in comparison to dual-energy quantitative computerized tomography. by Link, J.M., M. Zwaan, H.D.Weiss, K.J. Borgis, B. Batge in: Fortschr. Rontgenstr. 158 (1993) ]. Rofo. 1994;160: Projects Memberships EANM; DGN; DGMP 17/1/18 European Union, Page 10 / 11

11 Other Relevant Information 17/1/18 European Union, Page 11 / 11